Welcome to the Python Learning Roadmap in 30 Days! This project is designed to guide you through a structured 30-day journey to learn the Python programming language from scratch and master its ...

Korean biopharmaceutical company Adel announced Monday that it has secured a license-out agreement worth up to $1.04 billion with multinational health care firm Sanofi for the development and ...

Adel (ADEL), which is jointly developing an Alzheimer's disease drug candidate with Oscotec, said on the 16th that it signed a technology transfer agreement with French drugmaker Sanofi to transfer ...

ADEL-Y01, a monoclonal antibody targeting tau protein, is in Phase I trials for Alzheimer's disease, developed by ADEL and licensed to Sanofi. The ADEL-Sanofi agreement is valued at over $1.04 billion ...

ADEL Inc., a biopharmaceutical company dedicated to developing therapies for neurodegenerative diseases, has entered into an exclusive worldwide license agreement with Sanofi, a multinational ...

Deal includes $80 million upfront payment, with total potential value up to $1.04 billion plus royalties ADEL grants exclusive worldwide rights for acetylated tau-targeting antibody 'ADEL-Y01' to ...

Shares in Sanofi rose 2% to €82.27 ($96.87) at market open on 16 December. LCV via Shutterstock.com. Following the disappointment of a multiple sclerosis (MS) trial readout this week, Sanofi has ...

Sanofi is back with its second pact of the day, this time announcing a licensing deal for a South Korean biotech’s antibody therapy designed to treat Alzheimer's disease. The French pharma is paying ...

SEOUL, South Korea, Dec. 15, 2025 /PRNewswire/ -- ADEL, Inc., a biopharmaceutical company dedicated to developing therapies for neurodegenerative diseases such as Alzheimer's Disease, today announced ...

Dec 16 (Reuters) - South Korea-based ADEL said late on Monday that it has entered a $1.04 billion partnership with ‌French drugmaker Sanofi to develop and sell the ‌biotech company's experimental ...

Dec 16 (Reuters) - South Korea-based ADEL said late on Monday that it has entered a $1.04 billion partnership with French drugmaker Sanofi (SASY.PA), opens new tab to develop and sell the biotech ...